APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/518,817 12/20/2004 Andrew Bailey 100727-1P US 9954 TITLE OF INVENTION: NEW USE OF PYRIMIDINE - OR TRIAZINE - 2 CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH	AUG-07-2006	MON 02:20 PM AZ	GIP WILMING	GTON	FAX NO.	3028868221	P. 01
Complete andwhald this form, together with applicable fee(s), to: Mail AUS 0 7 1005 AUS 0 7 1006	DE		PART B	- FEE(S) TR.	ANSMITTAL		
INSPECTIONS 2016 mm should be used for transmitting the ISSUE FEE and PUBLICATION SEE (if required). Blocks I through 5 should be completed when provided the publication of the current compression of the cu	Complete and send this form, together with applicable fee(s), to: Mail				Mail Stop IS Commission P.O. Box 145 Alexandria,	50 Virginia 22313-1450 85	<u>/</u> .
CURRENT CORRESPONDENCE ADDRESS Power Use Block 1 for my change of entires) 23466 7390 0607/2006 ASTRA ZENECA PHARMACEUTICALS LP GLOBAL INTELLECTUAL PROPERTY 1800 CONCORD PIKE WILMINGTON, DE 19850-5437 Concident of the property of the tith Foody Transmission 1. Interty cortify that this Foody Transmission 1. Interty cortified the Foody Transmission 1. Interty cortified the Interty cortified the Foody Transmission 1. Interty cortified the Inte	INSTRUCTIONS ON S for appropriate AND Firther con indicated unless corrected to	m should be used for tran respondence including the l clow or directed otherwise	smitting the ISSU atent, advance or in Block 1, by (a	E FEE and PUB! ders and notificati) specifying a new	LICATION FEE (i on of muintenanco v correspondence bu	f required). Blocks 1 through 5 foes will be mailed to the currer ddress; and/or (b) indicating a se	should be completed where it correspondence address at parate "FBE ADDRESS" for
ASTRA ZENECA PHARMACEUTICALS LP GLOBAL INTELLECTUAL PROPERTY 1800 CONCORD PIKE WILMINGTON, DE 19850-5437 APPLICATIONNO. FILING DATE FIRST NAMED INVENTOR INVENTOR INVENTOR OF THE AUTOMOTE PROPERTY 1710 CONTROL OF THE PROPERTY 1711 CONTROL OF THE PROPERTY 1711 CONTROL OF THE PROPERTY 1711 CONTROL OF THE PROPERTY 1712 CONTROL OF THE PROPERTY 1712 CONTROL OF THE PROPERTY 1713 CONTROL OF THE PROPERTY 1714 CONTROL OF THE PROPERTY 1715 CONTROL OF THE PROPERTY (Indication of The Address of the Property of Agents of The Private Open and Seal Property of CONTROL OF THE PROPERTY (Indication of The Private Open and Seal Property of CONTROL OF THE PROPERTY (Indication of The Private Open and Seal Property of CONTROL OF THE PROPERTY (Indication of The Private Open and Seal Property of CONTROL OF THE PROPERTY (Indication of The Private Open and Seal Property of CONTROL OF THE PROPERTY (Indication OF CONT					Note: A certific Fec(s) Transmit papers. Each ad- have its own cer	ate of mailing can only be used al. This certificate cannot be used ditional paper, such as an assigna- tificate of mailing or transmission.	for domestic mailings of the for any other accompanying tent or formal drawing, must
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/518.817 12/20/2004 Andrew Bailey 100727-1P US 9954 11/1LC OF INVENTION: NEW USE OF PYRIMIDINE - OR TRIAZINE - 2 CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROSTEASE ACTIVITY AND NOVEL PYRIMIDINE-2-CARBONITILE DERIVATIVES 88/87/2886 (NGIJYEN) 88889183 269166 18518817 88/87/2886 (NGIJYEN) 88889183 269166 18518817 88/87/2886 (NGIJYEN) 88889183 269166 18518817 88/87/2886 (NGIJYEN) 88/889183 269166 18518817 88/889183 269166 18518817 88/87/2886 (NGIJYEN) 88/889183 269166 18518817 88/87/2886 (NGIJYEN) 88/889183 269166 18518817 88/87/2886 (NGIJYEN) 88/87/2886 (NGIJYE	ASTRA ZENECA PHARMACEUTICALS LP GLOBAL INTELLECTUAL PROPERTY 1800 CONCORD PIKE					O 110	
APPLICATIONNO. FILING DATE PRIST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/518.817 12/20/2004 Andrew Bailey 100727-1P US 9954 TITLE OF INVENTION: NEW USB OF PYRIMIDINE - OR TRIAZINE - 2 CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH 68/87/2006 CHGUYENI 80000103 260166 10518817 APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FROM THE PRIST OF TRIADED ON THE PRIST OF TRI	WILMINGTON, DE 19850-5437				Liz	Oak Las	(Depositor's name)
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/518.817 12/20/2004 Andrew Bailey 10/518.817 12/20/2004 Andrew Bailey 10/518.817 12/20/2004 Andrew Bailey 10/518.817 12/20/2004 PYRIMIDINE - OR TRIAZINE - 2 CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH 88/80/70/2006 CNGUYENI 89898193 269166 18518817 88/80/70/2006 CNGUYENI 89898193 269166 1851817 89/70/2006 CNGUYENI 89/70/2006 CNGUYENI 89898193 269166 1851817 89/70/2006 CNGUYENI 89/70/2006 CNGUYENI					(Xis	apritor	(Signaturo)
Andrew Bailey 100727-1P US 9954						87106	(Dute)
TITLE OF INVENTION: NEW USE OF PYRIMIDINE - OR TRIAZINE - 2 CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH OBJECT INVENTION: NEW USE OF PYRIMIDINE-2-CARBONITILE DERIVATIVES 08/07/2086 CNGUYENI 08/08/09/3083 26/0166 18/05/08/07/2086 STAIL ENTITY	APPLICATION NO.	FILING DATE	FIRST NAMED INV		ENTÓR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
TITLE OF INVENTION: NEW USE OF PYRIMIDINE - OR TRIAZINE - 2 CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROSTEASE ACTIVITY AND NOVEL PYRIMIDINE-2-CARBONITILE DERIVATIVES 1	10/518 817	12/20/2004 Andrew Bai			cy	100727-1P US	9954
SAMINER ART UNIT CLASS-SUBCLASS	TITLE OF INVENTION: I	CTIVITY AND NOVEL P	YRIMIDINE-2-CA	ARBONITILE DE	RIVATIVES &	18/8//2006 CNGUYENI 00000:	103 260166 10518817
BALASUBRAMANIAN, VENKATARAMAN 1624 514-269000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.36 a). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address findication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignce is identified below, no assignce data will appear on the patent. If an assignce is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) AstraZeneca AB Sodertalje, Sweden 4b. Payment of Fee(s): A check in the amount of the fee(s) is onclosed. Pleuse check the appropriate assignee category or categories (will not be printed on the patent): A check in the amount of the fee(s) is onclosed. Payment of Fee(s): A check in the amount of the fee(s) is onclosed. Payment by credit card. Form PTO-2018 is attached. The Director is horeby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number et al. (2011) a.	APPLN, TYPE	SMALL ENTITY	ISSUE FEE				
BALASUBRAMANIAN, VENKATARAMAN 1624 514-269000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SB/122) attached. Change of correspondence address or indication of the fee Address from PTO/SB/122) attached. Change of correspondence address or indication of The Correspondence Address from PTO/SB/122) attached. Change of correspondence address or indication of The Correspondence Address from PTO/SB/122) attached. Change of correspondence address or indication of The Correspondence Address from PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address from Pto/SB/1222) attached. Change of correspondence address (or Change of Correspondence Address from Indication Indication Indication Indication Indication I	nonprovisional	NO	\$1400) 	\$300	\$1700	09/07/2006
Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address (or Change of Correspondence Address from PTO/SB/122) attached. "Fee Address" indication (or "Tee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. AstraZeneca AB Sodertalje, Sweden	EXAMINER		ART UNIT		CLASS-SUBCLASS		
CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignment is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE AstraZeneca AB Please check the appropriate assignee category or categories (will not be printed on the patent): Individual Corporation or other private group entity Government. 4b. Payment of Fee(s): Sodertalje, Sweden Please check the appropriate assignment entity discount permitted) Advance Order - # of Copies 10 (Single Form). Advance Order - # of Copies 10 (Copies In a copy of this form).	BALASUBRAMANIAN, VENKATARAMAN		1624		514-26 9 000	<u> </u>	
PLEASE NOTE: Unless an assigned is identified below, no assigned data will appear on the patent. If an assigned is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) AstraZened AB Sodertalje, Sweden Please check the appropriate assigned category or categories (will not be printed on the patent): Individual Corporation or other private group entity Government of the fee(s): At the following fee(s) are enclosed: Issue Fee Publication Fee (No small entity discount permitted) Advance Order - # of Copies 10	CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer			(1) the names of or agents OR, a (2) the name of registered attor 2 registered pat	of up to 3 registered lternatively, I a single firm (havi ney or agent) and the cent attemneys or age	patent attorneys I Jianz	nong Shen
Please check the appropriate assignce category or categories (will not be printed on the patent):	PLEASE NOTE: Unless recordation as set forth in (A) NAME OF ASSIGN	en assignee is identified be 37 CFR 3.11. Completion EE	E PRINTED ON Tolow, no assignce of this form is NO	data will appear of a substitute for fine (B) RESIDENCE	on the patent. If an illing an assignment. It (CITY and STAT)	E OR COUNTRY)	document has been filed fo
4a. The following fec(s) are enclosed: ————————————————————————————————————					_	-	
A check in the amount of the fee(s) is onclosed. A publication Fee (No small entity discount permitted) A check in the amount of the fee(s) is onclosed. Payment by credit card. Form PTO-2038 is attached. Payment by credit card. Form PTO-2038 is attached. A check in the amount of the fee(s) is onclosed. Payment by credit card. Form PTO-2038 is attached. A check in the amount of the fee(s) is onclosed. Payment by credit card. Form PTO-2038 is attached. A check in the amount of the fee(s) is onclosed. Payment by credit card. Form PTO-2038 is attached. Payment by credit card. Form PTO-2038 is attached. A check in the amount of the fee(s) is onclosed. Payment by credit card. Form PTO-2038 is attached. Payment by credit card. Form PTO-2038	Please check the appropriate	assignce category or catego	ries (will not be pr	inted on the patent): Undividual	Corporation or other private g	tromb cutty - Governmen
	Issue Fee Issue Fee A Publication Fee (No s Advance Order - # or	mall entity discount permitte Capies 10	ed)	A check in the	amount of the fee(D-2038 is attached.	redit any overpayment, to tra copy of this form).

Authorized Signature

Typed or printed name

Jianzhong Shen

Date Hus. +, 2006

ated name Jianzhong Shen Registration No. 48,076

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.